Pemigatinib (Pemazyre) is a precision-targeted therapy for tumors with FGFR gene abnormalities. It has been approved for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (with FGFR2 fusion or other rearrangements) and relapsed or refractory FGFR1-rearranged myeloid/lymphoid neoplasms (MLN).

Where to Purchase Pemigatinib (Pemazyre)

Overseas Purchase

Patients may choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries/regions where pemigatinib has been approved for marketing.

Since drug prices may be affected by regional differences, exchange rate fluctuations and other factors, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Providers

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels, as well as professional consultation and guidance services.

Precautions for Pemigatinib (Pemazyre)

Pre-treatment Medical Assessment Procedures

Genetic Testing Confirmation: Cholangiocarcinoma patients must be tested for FGFR2 fusion/rearrangements; MLN patients must be confirmed to have FGFR1 rearrangements.

Standard Dosage Regimens

Cholangiocarcinoma: 13.5 mg once daily, administered continuously for 14 days followed by a 7-day drug holiday, forming a 21-day treatment cycle.

MLN: 13.5 mg once daily, administered continuously.

Administration Instruction: Swallow the tablets whole; do not chew, crush, or dissolve the tablets.

Dosage Adjustments for Special Populations

Severe renal impairment (eGFR 15–29 mL/min/1.73 m²): Adjust the dose to 9 mg.

Severe hepatic impairment (total bilirubin > 3 × ULN): Adjust the dose to 9 mg.

Ocular Toxicity Management

Retinal Pigment Epithelial Detachment (RPED): Incidence rate of 11%.

Dry Eye Disease: Incidence rate of 31%.

Prevention and Treatment Measures: Conduct a comprehensive ophthalmologic examination including Optical Coherence Tomography (OCT) before treatment; re-examine every 2 months during the initial treatment phase, and every 3 months after 6 months of treatment.

Identification of Authentic Pemigatinib (Pemazyre)

Verification of Packaging Characteristics

4.5 mg strength: Round, white to off-white tablets, engraved with "I" on one side and "4.5" on the other side.

9 mg strength: Oval, white to off-white tablets, engraved with "I" on one side and "9" on the other side.

13.5 mg strength: Round, white to off-white tablets, engraved with "I" on one side and "13.5" on the other side.

Bottle Packaging Specification: 14 tablets per bottle, equipped with a child-resistant cap.

Identification of Physical Properties

Tablet Color: White to off-white.

Engraving Feature: Clear and free of wear.

Packaging Integrity: Intact and well-sealed.